Organogenesis (ORGO) commends the decision by the U.S. Centers for Medicare & Medicaid Services on local coverage determination based on peer-reviewed and evidence-based data of clinical efficacy. The LCD covers skin substitute grafts/cellular and tissue-based products for the treatment of diabetic foot ulcers and venous leg ulcers in the Medicare population and is now set to become effective on February 12, 2025. Organogenesis offers 4 products for DFUs, including NuShield, and 2 for VLUs.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ORGO:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue